Streamlined.financeStreamlined.finance
MarketsFind Stocks

Bio-Techne Corporation

NASDAQ

Market Cap.

12.06B

Avg. Volume

902.53K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Bio-Techne Corporation

Bio-Techne Corporation News

Bio-Techne Corporation Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareBiotechnology
bio-techne.com

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Bio-Techne Corporation Earnings & Revenue

Bio-Techne Corporation Financials

Table Compare

Compare TECH metrics with:

   

Earnings & Growth

TECH

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

TECH

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

TECH

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

TECH

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Bio-Techne Corporation Income

Bio-Techne Corporation Balance Sheet

Bio-Techne Corporation Cash Flow

Bio-Techne Corporation Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsNeutral
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioSell
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Bio-Techne Corporation Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

0.3200

Payment DateDividendFrequency
2024-08-300.08Quarterly
2024-05-240.08Quarterly
2024-02-260.08Quarterly
2023-11-240.08Quarterly
2023-09-010.08Quarterly

Bio-Techne Corporation Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Historical Market Cap

Shares Outstanding

Bio-Techne Corporation Executives

NameRole
Mr. Kim KeldermanChief Executive Officer, President & Director
Mr. James T. HippelExecutive Vice President of Finance & Chief Financial Officer
Mr. William A. GeistPresident of Protein Sciences Segment
Dr. Matthew F. McManus M.D., MBA, Ph.D.President of Diagnostics & Genomics
Mr. Shane BohnenSenior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer
NameRoleGenderDate of BirthPay
Mr. Kim KeldermanChief Executive Officer, President & DirectorMale19671.06M
Mr. James T. HippelExecutive Vice President of Finance & Chief Financial OfficerMale1971924.74K
Mr. William A. GeistPresident of Protein Sciences SegmentMale1969709.94K
Dr. Matthew F. McManus M.D., MBA, Ph.D.President of Diagnostics & Genomics1969659.01K
Mr. Shane BohnenSenior Vice President, General Counsel, Corporate Secretary & Chief Sustainability OfficerMale1975430.77K

Bio-Techne Corporation Insider Trades

Date24 Oct
NameKEEGAN JOSEPH D
RoleDirector
TransactionAcquired
TypeA-Award
Shares1462
Date24 Oct
NameKEEGAN JOSEPH D
RoleDirector
TransactionAcquired
TypeA-Award
Shares3511
Date24 Oct
NameVESSEY RUPERT
RoleDirector
TransactionAcquired
TypeA-Award
Shares1462
Date24 Oct
NameVESSEY RUPERT
RoleDirector
TransactionAcquired
TypeA-Award
Shares3511
Date24 Oct
NameBushman Julie L
RoleDirector
TransactionAcquired
TypeA-Award
Shares1462
DateNameRoleTransactionTypeShares
24 OctKEEGAN JOSEPH DDirectorAcquiredA-Award1462
24 OctKEEGAN JOSEPH DDirectorAcquiredA-Award3511
24 OctVESSEY RUPERTDirectorAcquiredA-Award1462
24 OctVESSEY RUPERTDirectorAcquiredA-Award3511
24 OctBushman Julie LDirectorAcquiredA-Award1462

Discover More

Streamlined Academy

Bio-Techne Corporation

NASDAQ

Market Cap.

12.06B

Avg. Volume

902.53K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Bio-Techne Corporation News

Bio-Techne Corporation Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

Bio-Techne Corporation Earnings & Revenue

Bio-Techne Corporation Income

Bio-Techne Corporation Balance Sheet

Bio-Techne Corporation Cash Flow

Bio-Techne Corporation Financials Over Time

Bio-Techne Corporation Executives

NameRole
Mr. Kim KeldermanChief Executive Officer, President & Director
Mr. James T. HippelExecutive Vice President of Finance & Chief Financial Officer
Mr. William A. GeistPresident of Protein Sciences Segment
Dr. Matthew F. McManus M.D., MBA, Ph.D.President of Diagnostics & Genomics
Mr. Shane BohnenSenior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer
NameRoleGenderDate of BirthPay
Mr. Kim KeldermanChief Executive Officer, President & DirectorMale19671.06M
Mr. James T. HippelExecutive Vice President of Finance & Chief Financial OfficerMale1971924.74K
Mr. William A. GeistPresident of Protein Sciences SegmentMale1969709.94K
Dr. Matthew F. McManus M.D., MBA, Ph.D.President of Diagnostics & Genomics1969659.01K
Mr. Shane BohnenSenior Vice President, General Counsel, Corporate Secretary & Chief Sustainability OfficerMale1975430.77K

Bio-Techne Corporation Insider Trades

Date24 Oct
NameKEEGAN JOSEPH D
RoleDirector
TransactionAcquired
TypeA-Award
Shares1462
Date24 Oct
NameKEEGAN JOSEPH D
RoleDirector
TransactionAcquired
TypeA-Award
Shares3511
Date24 Oct
NameVESSEY RUPERT
RoleDirector
TransactionAcquired
TypeA-Award
Shares1462
Date24 Oct
NameVESSEY RUPERT
RoleDirector
TransactionAcquired
TypeA-Award
Shares3511
Date24 Oct
NameBushman Julie L
RoleDirector
TransactionAcquired
TypeA-Award
Shares1462
DateNameRoleTransactionTypeShares
24 OctKEEGAN JOSEPH DDirectorAcquiredA-Award1462
24 OctKEEGAN JOSEPH DDirectorAcquiredA-Award3511
24 OctVESSEY RUPERTDirectorAcquiredA-Award1462
24 OctVESSEY RUPERTDirectorAcquiredA-Award3511
24 OctBushman Julie LDirectorAcquiredA-Award1462

Streamlined Academy

Website screenshot
HealthcareBiotechnology
bio-techne.com

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Bio-Techne Corporation

Bio-Techne Corporation Financials

Table Compare

Compare TECH metrics with:

   

Earnings & Growth

TECH

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

TECH

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

TECH

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

TECH

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Bio-Techne Corporation Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

0.3200

Payment DateDividendFrequency
2024-08-300.08Quarterly
2024-05-240.08Quarterly
2024-02-260.08Quarterly
2023-11-240.08Quarterly
2023-09-010.08Quarterly

Bio-Techne Corporation Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsNeutral
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioSell
Price/Earnings RatioStrong Sell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

A Practical Guide: How To Analyze Any Stock (With Examples)